"La Clinique CHC MontLégia est un hôpital flambant neuf construit sur le site de Patience et Beaujonc à l’entrée ouest de Liège. Elle a été mise en service en mars 2020, et regroupe l’activité des anciennes cliniques Saint-Joseph, Espérance et Saint-Vincent. Notre nouvel hôpital propose une offre de soins complète (hospitalisation, consultations, examens médicaux) et dispose d’un équipement de dernière génération. La lumière naturelle, le confort des chambres avec une belle vue sur la ville, l’ergonomie du bâtiment, l’accessibilité constituent quelques-uns des atouts de la Clinique CHC MontLégia."

During the past decade, CHC MontLégia conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 4 clinical trials were completed, i.e. on average, 9.8% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 4 clinical trials were completed. i.e. 14.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHC MontLégia" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Janssen Research & Development, LLC" with 6 trials sponsored, "Celgene" with 3 trials sponsored, "University of Liege" with 3 trials sponsored and "Belgian Group of Digestive Oncology" with 3 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHC MontLégia" #1 collaborator was "Breast International Group" with 2 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Cancer Research UK" with 1 trials as a collaborator, "Frontier Science & Technology Research Foundation, Inc." with 1 trials as a collaborator and "Gynecologic Oncology Group" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "CHC MontLégia" are "Crohn Disease" (6 trials), "Crohn's Disease" (3 trials), "Atrial Fibrillation" (2 trials), "Colitis, Ulcerative" (2 trials) and "Acute Ischemic Stroke" (1 trials). Many other conditions were trialed in "CHC MontLégia" in a lesser frequency.

Most popular intervention types in "CHC MontLégia" are "Drug" (30 trials), "Other" (7 trials), "Biological" (3 trials), "Device" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Atezolizumab" (3 trials), "Guselkumab" (3 trials), "Ozanimod" (3 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "CHC MontLégia" are 37 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CHC MontLégia". undefined are not yet recruiting, 21 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in CHC MontLégia, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in CHC MontLégia, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".